Stockpolly
Search
Delisting risk
CDT · NASDAQ · Biotechnology

CDT Equity (CDT)

Develops and out-licenses repurposed clinical assets through solid-form chemistry, computational analysis, and patent creation.

$0.8888
Pre-market−0.03 (−3.17%)
At close$0.9179(−37.98%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000000696750
Cost of revenue0000000000438449
Gross profit0000000000258301
01336445721180184
Research & development00003012213033
01333333620139151
General & administrative013333336201390
Other expenses0000000000110
Operating income0−1−3−3−6−4−4−5−7−2178117
33−1−2−11−1−100−15−32
Interest income000000000000
Interest expense000001000013−41
Other non-operating income−3−3020−211002−10
Income before tax32−4−5−6−2−5−6−7−216385
Income tax expense00000000001217
Net income from continuing operations32−4−5−6−2−5−6−7−215169
Net income32−4−5−6−2−5−6−7−215169
EPS, basic$12,039.00$723.00−$1,451.10−$2,186.70−$2,223.90−$521.10−$366.95−$109.25−$32.90−$23.14$131.00$1.76
EPS, diluted$1,977.00$670.96−$1,451.10−$2,186.70−$2,223.90−$521.10−$366.95−$109.25−$32.90−$23.14$130.00$1.74
Weighted average shares, basic0———000001039
Weighted average shares, diluted0———000001039
EBITDA32−318−6−1−4−5−6−19109160
Depreciation & amortization000240001123232
EBIT32−3−5−6−1−5−6−7−2176127